Krijbolder et al on MTX to prevent RA in clinically suspect arthralgia. No effect on arthritis free survival (80 vs 82%). Some delay in RA onset in high-risk group. But there was a sustained improvement in symptoms in MTX group @RheumNow #EULAR2022 OP0070 https://t.co/0CPIP51yQd https://t.co/kWNmw1YzrH

• EULAR Abstract Archive

NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

• EULAR Abstract Archive

NORD-STAR TRIAL drug does better in ttmt naive eRA? 48wks CDAI remission ▶️ w/ ABA and CERTO PEG vs. MTX+ GCs while TCZ not stat ▶️. Is the difference clinically sufficient to recommend these in first intention over MTX ? not convinced 🧐 OP0058 #EULAR22 @rheumnow

Damien et al on Whipple's Disease presenting as RMD. 73 cases (wow!) Treat Whipples, 93% remission, 94% off DMARD @RheumNow #EULAR2022 OP0066 https://t.co/XQnQq4RNcq

• EULAR Abstract Archive

10 year study showed NSAIDs associated with slowing radiographic progression in axSpA patients. mSASSS progression numerically lower in COX2i pts compared to non-selective NSAIDs. @RheumNow #EULAR2022 #ABSTOP0021 https://t.co/dfz3rseikl

Combination tx of NSAIDs and TNFi (celecoxib and golimumab) did not show significant superiority compared to TNFi alone in slowing radiographic progression for treatment of radiographic axSpA. There was a numerical reduction however. #EULAR2022 @RheumNow #ABSTOP0018 https://t.co/gUZAwd92dK

@Rheumnow #EULAR2022 POS0240 ▶️ In 2021, 73.6% of Belgian RA patients staring a JAKi, started a 2nd generation JAKi (UPA, FIL). Predictors for 1st generation usage (BAR, TOFA): older age, prior DMARD therapies. What would you start as a first JAKi?

ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI